Selemix Launches NGS-Based Comprehensive Cancer Companion Diagnostic Panel 'CancerScreen CDx'

[Asia Economy Reporter Lee Gwan-joo] Selemix, a genetic analysis technology platform company, announced on the 10th that it has launched the NGS-based comprehensive cancer companion diagnostic panel 'CancerScreen CDx.'

This product analyzes 23 cancer genes at once, enabling simultaneous analysis of companion diagnostic markers for most targeted anticancer drugs currently approved by the U.S. Food and Drug Administration (FDA).

The panel released by Selemix can analyze mutations related to various cancer types such as lung cancer, colorectal cancer, breast cancer, skin cancer, and prostate cancer all at once. It analyzes SNV, CNV, and rearrangement mutations occurring in more than 20 genes including ALK, BRAF, EGFR, FGFR, KRAS, MET, ROS1, and NTRK, allowing simultaneous analysis of various companion diagnostic markers related to over 40 targeted anticancer drugs such as Afatinib, Cetuximab, Crizotinib, Gefitinib, Olaparib, Infigratinib, Larotrectinib, and Entrectinib.

Existing testing methods sequentially examine mutations starting from the most common ones, which results in a long time to obtain results for multiple mutations. Additionally, for mutations tested later, there may be insufficient specimens available, making testing difficult. In contrast, the NGS testing method can examine multiple genes at once, reducing the time required compared to existing methods and requiring less specimen volume, thereby overcoming the limitations of insufficient tissue for testing in conventional methods.

Selemix explained that their newly developed NGS-based comprehensive cancer companion diagnostic panel selectively tests only the molecules related to companion diagnostic markers for targeted anticancer drugs within the entire human DNA. This significantly increases data density compared to conventional NGS, improving test accuracy while reducing testing costs.

Meanwhile, Selemix launched a companion diagnostic product development service for pharmaceutical companies in October last year, and plans to strengthen business cooperation with global pharmaceutical companies and large hospitals through the release of this panel.

This content was produced with the assistance of AI translation services.